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High-Frequency Oscillation for ARDS
To the Editor: In their article on the Oscillation 
for Acute Respiratory Distress Syndrome Treated 
Early (OSCILLATE) study, Ferguson et al. (Feb. 28 
issue)1 report increased mortality in patients 
with the acute respiratory distress syndrome 
(ARDS) who underwent high-frequency oscilla-
tory ventilation (HFOV), probably because of el-
evated mean airway pressures. High levels of air-
way pressure may reduce venous return by 
elevating right atrial pressure, increasing venous 
resistance, and creating vascular waterfall condi-
tions in the vena cava.2,3 High levels of airway 
pressure may also increase pulmonary vascular 
resistance and right ventricular afterload through 
passive compression of alveolar vessels.4 During 
HFOV, the mean airway pressure is a setup mea-
sure but is a dependent variable during conven-
tional mechanical ventilation. It is influenced by 
inspiratory, expiratory, and total cycle times, al-
veolar pressure, tidal volume, inspiratory resis-
tance, and positive end-expiratory pressure 
(PEEP)5 (Fig. 1). The data presented by Ferguson 
et al. suggest that we should consider control of 
the mean airway pressure for circulatory protec-
tion of patients with ARDS who are undergoing 
mechanical ventilation, just as we learned to lim-
it plateau pressure for lung protection.
Lucas Liaudet, M.D.
University Hospital Medical Center 
Lausanne, Switzerland 
lucas.liaudet@chuv.ch
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To the Editor: Ferguson et al. found that the 
use of HFOV for the treatment of early ARDS was 
associated with an absolute increase of 12 per-
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Figure 1. Determinants of Mean Airway Pressure.
The mean airway pressure is influenced by the inspira-
tory time (Ti), expiratory time (Te), and total cycle time 
(Tt), along with the time integral of the function of alveo-
lar pressure (PA) during inspiration (dt), tidal volume (Vt), 
inspiratory resistance (Ri), and positive end-expiratory 
pressure (PEEP).
The New England Journal of Medicine 
Downloaded from nejm.org at CTR HOSPITAL UNIVERSITAIRE VAUDOIS on October 27, 2017. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 368;23 nejm.org june 6, 20132232
centage points in the rate of death, as compared 
with conventional ventilation. We are concerned 
that systematic differences between the sedation 
strategies used in the two study groups may ex-
plain the findings, as we discussed regarding the 
study of neuromuscular blockers for early ARDS 
reported by Papazian et al.1,2
Perception of discomfort associated with 
HFOV may predispose physicians to prescribe 
higher doses of vasodilating sedatives and analge-
sics than with conventional ventilation (approxi-
mately 750 μg of fentanyl and 50 mg of midazo-
lam more per day with HFOV), a finding that 
was associated with the administration of an 
additional liter of fluid over the first 3 days to 
maintain hemodynamic stability. In the Sepsis 
Occurrence in Acutely Ill Patients	(SOAP) trial, 
investigators found an absolute increase in mor-
tality of 10 percentage points for each liter of 
fluid accumulated during the first 72 hours,3 a 
finding that approximated the increase in mor-
tality reported in the study by Ferguson et al.
Perhaps if the anesthetic prescription includ-
ed ketamine (similar to that used in the group 
receiving neuromuscular blocking agents in the 
study by Papazian et al.1), the combination of the 
opiate-sparing and vasoconstricting effects of 
ketamine4 would attenuate sedation-related fluid 
requirements, and the benefit of HFOV would be 
realized.
Robert C. McDermid, M.D.
University of Alberta 
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To the Editor: The OSCILLATE study and the 
Oscillation in ARDS (OSCAR)1 trial by Young et al. 
have provided robust data on the outcome of 
HFOV among patients with ARDS. However, we 
wonder whether the key message — namely, the 
critical importance of lower tidal volumes in con-
ventional ventilation — should be taken from 
considering the two studies together. Illness-
severity scores were lower at randomization in 
the OSCAR study than in the OSCILLATE study. 
However, the control group in the OSCAR study 
had a rate of death of 41.1%, whereas the rate of 
death in the OSCILLATE study was 35%. Al-
though the ventilation protocols in the control 
groups seem similar, in the OSCILLATE study, 
investigators were more successful in delivering 
low tidal volumes. In the OSCAR study, the deliv-
ered tidal volumes were just over 8 ml per kilo-
gram of body weight. The original study by the 
ARDS Network2 showed the importance of tar-
geting a low tidal volume. Needham et al.3 
showed that ventilation with tidal volumes of less 
than 6.5 ml per kilogram was associated with a 
survival advantage, as compared with even mod-
estly higher values (6.5 to 8.5 ml per kilogram). 
It would appear that the control groups in the 
OSCILLATE and OSCAR studies reveal a major 
difference in practice, which resulted in a sur-
vival difference.
Andrew MacDuff, M.R.C.P. 
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To the Editor: In experimental models of lung 
failure, the use of HFOV improves oxygenation 
and reduces lung injury, as compared with low-
tidal-volume ventilation.1 However, neither the 
OSCILLATE study nor the OSCAR study was able 
to translate this benefit from bench to bedside. 
Two factors are at play. First, both the time of 
initiation of HFOV and the type of lung injury are 
crucial determinants of the potential for lung re-
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cruitment. The inclusion of patients receiving 
mechanical ventilation for up to 1 week and the 
high prevalence of direct lung injury may have 
contributed to the reported lack of benefit for 
HFOV. Second, HFOV is a complex technique re-
quiring high levels of expertise and is associated 
with a considerable learning curve. Although we 
note the efforts to train personnel at the experi-
mental sites, for the studies to be credible, there 
needs to be a verifiable demonstration of skill in 
the use of HFOV by all operators.
Ralf M. Muellenbach, M.D., Ph.D. 
Markus Kredel, M.D. 
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To the Editor: We think that the methods that 
were used to set mean airway pressure in the 
OSCAR and OSCILLATE trials were sufficiently 
different to be clinically meaningful. In the 
 OSCAR trial, the mean airway pressure was set at 
5 cm of water above the pressure recorded in 
conventional ventilation, whereas it was set ac-
cording to levels of the fraction of inspired oxy-
gen in the OSCILLATE trial. Therefore, in the 
OSCILLATE trial, the mean airway pressure was 
greater in the HFOV group at day 1 than in the 
control group, and the difference persisted dur-
ing the first week. We have found that the use of 
a mean airway pressure of more than 5 cm above 
the level of airway pressure recorded during con-
ventional ventilation was not associated with bet-
ter oxygenation but was associated with a de-
crease in cardiac output by worsening right 
ventricular function.1 This mechanism probably 
occurred in patients in the OSCILLATE study, in 
which the HFOV group had higher use of vaso-
pressors after initiation of the protocol than did 
the control group.
Christophe Guervilly, M.D. 
Antoine Roch, M.D., Ph.D. 
Laurent Papazian, M.D., Ph.D.
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Dr. Ferguson and colleagues reply: Differ-
ent ventilatory strategies have varying conse-
quences on many physiological and biologic pro-
cesses, including gas exchange, hemodynamics, 
ventilator-induced lung injury, and patient com-
fort, which often makes it difficult to predict the 
effects of these strategies on outcome. Each of 
the correspondents highlights this fact and shows 
why clinical trials are necessary to weigh the 
positive and negative effects of different aspects 
of any given ventilatory strategy.
As discussed in our article, we agree with 
Liaudet and with Guervilly and colleagues that 
higher mean airway pressures in the HFOV group 
may have contributed to excess mortality. After 
the publication of the study by Guervilly et al., 
which suggested worsening right ventricular 
function on echocardiography with HFOV, the 
OSCILLATE steering committee discussed wheth-
er there should be any changes to the protocol.1 
Given the uncertain clinical relevance of their 
findings, the potential benefits of higher mean 
airway pressures in mitigating ventilator-induced 
lung injury, and expert recommendations under-
lying our protocol,2 we did not change the proto-
col but recommended that investigators consider 
performing echocardiography in study partici-
pants receiving HFOV.
We agree with McDermid and Csányi-Fritz 
that increased sedation and fluid administration 
could have contributed to the increased mortal-
ity in the HFOV group, although the relative 
importance of this mechanism is unclear. Obser-
vational data such as those obtained in the SOAP 
study may be confounded by severity of illness. 
Indeed, data from randomized trials have shown 
that large differences in sedative administration 
were not associated with differences in mortality.3
We agree with MacDuff and Holland that the 
conventional ventilation strategy used in the con-
trol group in our study (i.e., low tidal volumes 
and higher PEEPs) may have contributed to our 
finding of better outcomes for conventional ven-
tilation. However, we urge caution in comparing 
the outcomes in control groups across studies, 
since even subtle differences in methods may 
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have important implications. For example, in the 
OSCAR study, severity of illness was calculated 
on admission, whereas we used data obtained 
24 hours before randomization, which may 
have resulted in systematic differences in scores 
on the Acute Physiology and Chronic Health 
Evaluation (APACHE) II between the studies.
As Muellenbach and colleagues point out, both 
the timing of HFOV initiation and the expertise 
of the personnel using the device may have im-
portant implications. We specified that patients 
be enrolled within 72 hours after meeting study 
inclusion criteria, and we enlisted centers in 
which there was substantial experience in using 
HFOV. Although we cannot attest to the exper-
tise of every clinician who cared for patients in 
the trial, we found no relationship between the 
number of patients studied per site (as a rough 
measure of experience) and mortality.
Niall D. Ferguson, M.D. 
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Dr. Young replies: MacDuff and Holland sug-
gest that the lower mortality in the OSCILLATE 
control group, which they attribute to the use of 
smaller tidal volumes in conventional ventilation 
than were used the OSCAR study, may have un-
masked the harm that HFOV was causing. This 
may be the case, although there might also have 
been differences between the two control groups 
that were not captured in the severity scores, 
demographic characteristics, or other recorded 
data that would account for the differences.
In the OSCAR study, we spent a considerable 
amount of time training participating critical 
care staff in the use of HFOV. It would not have 
been appropriate to introduce a new mechanical 
ventilator to critical care units without this 
training, whether in the context of a trial or not. 
In clinical trials of interventions that require 
training, it is not uncommon to look at the results 
to see whether the effect size changes as units 
recruit more patients, suggesting a learning ef-
fect. We are currently looking into this issue.
Guervilly and colleagues suggest that in the 
OSCILLATE study, the higher mean airway pres-
sure in the HFOV group than in the control 
group may account for the increased early use of 
vasoactive drugs in this group. In the OSCAR 
study, the mean pressure was not recorded in the 
control group, so we cannot determine whether 
it was the same as that in the HFOV group. There 
was no significant between-group difference in 
the use of vasoactive drugs in the OSCAR study, 
as recorded as the proportion of patients receiv-
ing these drugs.
Duncan Young, D.M.
John Radcliffe Hospital 
Oxford, United Kingdom
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Myths, Presumptions, and Facts about Obesity
To the Editor: Casazza et al. (Jan. 31 issue)1 
state that the common notion that “regularly 
eating (versus skipping) breakfast is protective 
against obesity” because people who skip break-
fast may overeat later in the day is currently noth-
ing more than a presumption. However, the evi-
dence they cite in support of this statement is 
more complex than they intimate. Examination 
of this evidence implies overcompensation (with 
increased food consumption later in the day after 
having skipped breakfast), but also undercom-
pensation depending on timing of meals.2,3 In 
addition, Casazza and colleagues do not ac-
knowledge the short-term nature of the available 
experimental research on which they focus exclu-
sively. Several surveys and a longitudinal study 
have negatively correlated body-mass index (BMI) 
with the frequency of eating breakfast, and mul-
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